← Eichor
Study identifier: NCT04552509 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

Condition: Prostate Cancer  ·  Sponsor: Linda Chan, MD

PhaseNA
Planned participants167
Who can joinMale, N/A to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to determine the effects of TrueBeam stereotactic body radiosurgery in patients with prostate cancer. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with your condition and to evaluate the effect of this treatment on your quality of life over time. Radiosurgery is a non-invasive treatment technique used to treat tumors. Despite the word "surgery" in the name, the technology does not remove the tumor with a surgical knife. Instead, a focused, high-intensity beam of radiation targets the tumor, while minimizing dose to surrounding normal healthy tissue.

This description comes directly from the study's public registry record.

Talk to the study team

Linda Chan, MD  ·  562-933-0300  ·  lchan@memorialcare.org

Always discuss trial participation with your own doctor first.

Locations (1)

MemorialCare Saddleback Medical CenterLaguna Hills, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04552509